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Abstract 
Bone has a high potential for endogenous self-repair. However, due to population 
aging, human diseases with impaired bone regeneration are on the rise. Current strategies 
to support bone healing include various biomolecules, cellular therapies, biomaterials and 
different combinations of these. Animal models for testing novel regenerative therapies 
remain the gold standard in pre-clinical phases of drug discovery and development. Despite 
improvements in animal experimentation, excessive poorly designed animal studies with 
inappropriate endpoints and inaccurate conclusions are being conducted. In this review, we 
discuss animal models, procedures, methods and technologies used in bone repair studies in 
an attempt to assist investigators in planning and performing scientifically sound 
experiments that respect the wellbeing of animals. In the process of designing an animal 
study for bone repair investigators should consider: skeletal characteristics of the selected 
animal species; a suitable animal model that mimics the intended clinical indication; an 
appropriate assessment plan with validated methods, markers, timing, endpoints and 
scoring systems; relevant dosing and statistically pre-justified sample sizes and evaluation 
methods; synchronization of the study with regulatory requirements and additional 
evaluations specific to cell-based approaches.  
 
 
 
 
 
 
 
Highlights 
• Animal models in bone regeneration studies remain the golden standard of testing 
• Advances in animal research are recommended to support the discovery of novel 
therapies 
• Animal skeleton features, the study models, the assessment plan, dosing and statistics 
should be considered 
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1. Introduction 
The already high incidence of bone trauma in the human population will inevitably 
increase as the human population ages. Osteoporosis as the major underlying condition 
makes approximately 27.6 million men and women in the EU (6 % of men and 21 % of 
women aged 50–84 years) to be susceptible to a bone fracture [1]. In 2010, approximately 
3.5 million bone fractures were reported in the EU with direct healthcare costs of € 37 billion 
and 1.180.000 quality adjusted life years lost [2]; these costs expected to undergo a 25% 
increase by 2025. Large bone defects as well as non-unions and extensive bone loss after 
fractures still remain challenges for efficient clinical interventions and require additional 
support of the damaged site. Because present therapeutic approaches are often 
accompanied with prolonged treatments, pain and risk of infection, haemorrhage, nerve 
damage and loss of function, there is a significant unmet medical need for the development 
of new options for bone repair and the prevention of bone non-unions. Various animal 
models are available to study the efficacy, safety and tolerability of new therapies. 
The objective of this review is to provide an overview of bone defect animal models 
and available tools for the assessment of bone healing, as well as to suggest guidelines for 
rational animal use in an attempt to advance bone research as well as to support the 
development of investigational products in bone regeneration. 
2. Bone regenerative strategies: biomolecules, cells and biomaterials 
Bone healing is a precisely orchestrated regenerative process, which restores the 
bone quality by mimicking embryological cascade of events. Bone healing process is 
traditionally divided into three stages: an early inflammatory stage, a repair stage and late 
remodelling [3]. A schematic presentation of a long bone healing stages and grades are 
presented in Figure 1A. 
Although bone possesses endogenous self-repair mechanisms [4-8], in conditions 
such as impaired blood supply, excessive damage to the periosteum, inadequate 
immobilization, infection at the affected area, mineral and vitamin deficiencies, underlying 
diseases and side effects of certain medications and radiation, the enhancement of the 
regenerative processes is necessary to ensure the rapid and adequate restoration of skeletal 
functions [9-11]. The standard therapy to treat bone fractures/defects includes mechanical 
support either via cast and/or mechanical devices (e.g. nails, plates and screws). Additional 
strategies being used and currently developed to further support bone healing are primarily 
based on the use of: (1) active ingredients (biomolecules), (2) cellular therapies and (3) 
biomaterials.  
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Figure 1. A: Tool for assessment and follow up of a long bone healing along the bone healing 
cascade expressed as a healing grade [12,13] and % of bone healed. The early phase of 
healing (grade 0-3) enables temporarily fracture stabilization and further endochondral bone 
formation, and is characterized by the recruitment of mesenchymal cells and successive 
chondrogenesis resulting in a soft callus formation [14]. The second stage (grade 4-5) is 
distinguished by deposition of the collagen and subsequent mineralization resulting in a 
woven bone formation. The last stage (grade 6) is characterized by the bone remodelling 
which restores the original bone structure and strength. The assessment of the healing 
process determines the sample size and end-points when planning an experiment. The 
scheme exemplifies a non-critical size defect healing. If one assumes that it depicts control 
animals, and that the grades “0” and “1” indicate average scores for an early process and 
grade “6” indicates an average score of a late process (6-8 weeks for a rat), then grades 0-1 
or 6 would be biased towards “no difference” between a control and treatment 
intervention. Hence, “mid-time” evaluation points (grades 2-5) are of interest for a 
comparison (see section 5 for more details). B: Suggested time points for the assessment of 
bone fracture healing in the mouse, rat, rabbit, pig, sheep, dog and non-human primates 
(NHP). Overall duration of an experiment and assessment time points in critical size defect 
studies should be extended for at least 30-40% of time used for a bone fracture (see section 
5, Figure 3A,B).  
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2.1. Biomolecules 
Biomolecules used in the regenerative therapies for bone are mainly various growth 
factors [15]. Osteogenic factors primarily belong to the TGF-β superfamily, and the most 
studied factors are bone morphogenetic protein BMP2, BMP4, BMP6 and BMP7 [16,17]. 
Because vascularization is essential for bone regeneration, angiogenic factors VEGF, PDGF, 
FGF and IGF are also being extensively tested for their usefulness in bone repair [18-24]. 
Immunomodulatory and anti-inflammatory agents, such as selective anti-cytokine therapies, 
corticosteroids and non-steroidal anti-inflammatory drugs, are used to direct specific effects 
on the regeneration and resorption pathways during bone healing [25,26]. Additionally, the 
use of parathyroidal hormone (PTH), growth hormone, steroids, calcitonin and vitamin D in 
systemic applications has also been shown to advance bone healing through stimulating 
osteogenesis, angiogenesis and osteoblast differentiation [27-30]. Various combinations of 
biomolecules have also been extensively evaluated in pre-clinical models with mostly 
positive results [27,31-37]. 
2.2. Cell-based therapy 
Cell-based therapy utilizes stem/progenitor mesenchymal cells originally identified 
among bone marrow stromal cells [38]. Although most studies were conducted with bone 
marrow derived mesenchymal progenitor cells (MPCs), other tissues have been described to 
contain osteoprogenitor cells with similar regenerative potential including adipose tissue, 
muscle, umbilical cord blood, periosteum, dental pulp and periodontal ligament [4,39-45]. 
The multilineage differentiation ability, paracrine effects and immunomodulatory properties 
of MPCs make them an ideal for tissue engineering and regenerative purposes [5,7,46-48]. 
Under appropriate conditions MPCs could be differentiated into a variety of mesenchymal 
tissues such as bone, cartilage, tendon, ligament, marrow stroma, muscle, fat and dermis 
[4,49-53]. To induce fracture healing, MPCs are expanded ex vivo prior to their autologous 
grafting to the fracture site and differentiated into osteogenic lineages to promote bone 
regeneration [9,54]. Such cell-based strategy approaches have been used to demonstrate 
that autologous bone marrow-derived MPC transplantation was superior compared to 
unloaded scaffold [5,7]. Unique immunological characteristics of MPCs suggest that the 
implantation of allogenic or xenogenic MPCs could be successfully used for a cell-based 
therapy. Cells of non-mesenchymal origin such as endothelial progenitor cells may also 
enhance bone regeneration by secreting paracrine osteoinductive and angiogenic factors [7]. 
Furthermore, tissue engineering, a process of developing biological tissue substituents for 
restoring, maintaining or improving tissue function [55], were used to construct a single 
device combining all of the important components of bone repair (osteoconductive scaffold, 
osteoinductive growth factors and osteogenic cells) [4,5,7,10,55-57]. Recent studies have 
attempted to improve the basic protocols of cell-based therapy via additional tissue 
engineering strategies, including alternative osteoprogenitor population, gene delivery 
modification of MPCs, growth factors or pharmacological compounds. Currently, more than 
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20 different clinical trials involving bone tissue engineering approaches using cell therapies 
are reported in Clinicaltrials.gov (www.clinicaltrials.gov).  
2.3. Biomaterials 
Starting from the natural materials such as bovine collagen which is currently raising 
safety concerns [58], the field of orthopaedic biomaterials has expanded to include an 
impressive array of materials that are currently being tested in preclinical models [59]. 
Biomaterials have a range of properties, from osteoinductive and osteoconductive to 
immunomodulatory. Hydroxyapatite and calcium phosphate as well as their composites such 
as HA/poly(DL-lactic-co-glycolic acid) (PLGA), in the form of ceramics, cements and coatings 
have shown osteoinduction in animal models [60-66]. Various hybrid materials combined as 
co-polymers, polymer blends and polymer-ceramic blends have also shown efficacy [67-73]. 
Advanced hydrogels, naturally derived collagen and gelatin gels as well as synthetic poly-
ethylene glycol and poly–vinyl alcohol-based hydrogels, serve as matrices for other products 
and mimic the extracellular matrix topography [74-76]. Biomaterials with 
immunomodulatory strategies, such as artificial extracellular matrices (ECMs) (hydrogels, 
ECM coatings) and materials with surface property modulation, have the ability to modify 
the immune function and improve bone repair and regeneration [25,77]. 
3. Overview of Methodology and Animal Models for Bone-healing Studies 
Working with animals is a privilege and scientist as well as their institutional ethical 
boards should do their best to conform to the current animal care guidelines [78,79]. In 
recent years, the regulatory and scientific community imposed stringent rules to ensure that 
the wellbeing of laboratory animals is respected and that the 3R’s paradigm implemented 
whenever possible without compromising the quality of the study and data analyses [80,81]. 
Despite copious improvements, too many animal studies are still being published without 
regard of their poor design, use of inadequate or insufficient biomarkers, inaccurate 
conclusions and/or producing insignificant data. The overall benefit of these studies to 
scientific community is negligible, with published studies being redundant and offering very 
little novelty. For instance, the BMP preclinical development is a telling example of the 
misuse of laboratory animals due to non-existent standard operating procedures for testing 
of novel compounds for bone regeneration. Large numbers of animal models, species and 
doses have been used to support the development of BMP2 and BMP7 devices, however 
majority of these studies yielded inconclusive results that were misleading and difficult to 
interpret. Between 1988 and 2004 hundreds of experiments were conducted on more than 
17.000 animals (literature search was performed via PubMed using terms bone 
morphogenetic protein 7 and bone morphogenetic protein 2, revealing 157 and 421 articles, 
respectively). In our opinion, literature based data represent only a small fraction of the total 
number of animals used. Despite this, after years of use in clinics both BMP devices have 
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been confronted with major side-effects and their clinical use has been recently scrutinized 
[17,82-84]. 
3.1. Principles of Study Design 
The analysis of hard tissues requires a long, complex and expensive experimentation. 
Scientists, clinicians and regulatory authorities have recognized the necessity of using two 
laboratory species and several independent biomarkers when assessing the effect of novel 
bone and fracture-healing therapies [85,86]. The first step when preparing a study is to 
precisely determine the study goals and establish the criteria used to evaluate the overall 
success of the study. The following step is to plan the study design in which ten essentials 
should be selected: 1) Animal model (optimizing goals of the study); 2) Animal species; 3) 
Animal sex and age; 4) Study duration (allowing for the biological process to initiate and 
complete); 5) Number of animals per study group (sufficient for statistical analyses); 6) Dose 
and route of administration of the test article (mimicking anticipated clinical use); 7) 
Appropriate controls (including a sham, vehicle and/or a “positive” control group to ensure 
the credibility and reproducibility of the data and a standard of care drug with a well-known 
efficacy/safety should be used as a “positive” control); 8) Supply of the test article (sufficient 
for the entire study); 9) Optimal in vivo and ex vivo biomarkers, and 10) Tissue collection, 
storage and analyses planning. The common wisdom of in vivo experimentation is often 
ignored for various reasons, most frequently due to a lack of experience and poor planning, 
a lack of funds, a lack of in-house expertise, short timelines and the inadequate selection of 
biomarkers. The publication of poorly designed studies on animals should be restricted for 
both ethical and scientific reasons. 
3.2. Methods and Technology 
All currently marketed drugs for the treatment of skeletal disorders, including 
fractures were successfully tested in preclinical models. The value of preclinical work 
involving animal models depends on two essentials. The first determinant depends on the 
availability of an animal model that mimics a human disease involving bone repair so that 
the data generated can be used to predict the drug efficacy and safety in patients. Examples 
of animal models with good predictability of clinical outcomes include models of 
postmenopausal osteoporosis [87-92], models of glucocorticoid induced bone loss [93-96], 
models of cancer metastasis to bone [97], disuse models [98,99], fracture healing models 
[100-103] and several others. The second determinant of successful experimentation relates 
to translational biomarkers of novel therapy efficacy and safety that can be accurately 
predicted and monitored in patients. Numerous methods that are thoroughly understood, 
extensively described and tested for predictability are available for testing the efficacy and 
safety of novel treatment targets (Table 1).   
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Table 1. The “toolbox” of methods and technologies that is available for in vivo and ex vivo 
assessment of bone physiology and pathology.  
 
IN VIVO ASSESSMENT 
Assessment Process/Parameter Assay/Technology Translation 
Biomarkers in serum and 
urine 
Bone formation, resorption,  
metabolism, cartilage 
formation, connective tissue 
degradation, calciotropic 
hormones  
P1NP, Osteocalcin, BSAP, CTX, TRAP5b, 
Ca
2+
, P
2- 
, PIIANP, ICTP, IGF-1, PTH, Vit. 
D, calcitonin, T3/T4  
High                                   
Imaging technologies 
Bone anatomy, bone mass, 
geometry, and structure 
Standard radiology, DEXA, pQCT, micro-
CT, MRI, PET, use of contrast agents 
High 
Functional tests Biomechanic/Biometric 
Dynamic Weight Bearing System, Gait 
analyses (Digigait), some other 
High 
Mechanical properties 
Bone strength: maximum 
load , stiffness, toughness, 
ultimate strength 
BioDent Too early 
EX VIVO ASSESSMENT 
Test Activity/Parameter Assay/Technology Translation 
Imaging technologies 
Local bone anatomy, bone 
geometry, bone mass, bone 
structure 
Standard radiology, DEXA, pQCT, micro-
CT, MRI, PET 
High 
Bone Biomechanics 
(strength) 
Bone geometry, composition 
and strength of cortical 
and/or cancellous bone 
Various methods (3- and 4-point 
bending methods, tensional test, 
compression test, Finite element 
modeling 
High 
Undecalcified bone 
histology and 
histomorphometry 
Bone remodeling and 
modeling at cortical bone 
envelopes, cancellous bone, 
Bone Formation Rate, 
Mineral Appositional Rate, 
osteoid, mineral 
Requires in vivo labeling with 
fluorescent markers, embedding in 
methylmetacrylate, cutting and 
analyses (histomorphometry) or 
staining (von Kossa, Goldner trichrome, 
Toluidine blue). Cryosections should be 
considered. 
High (if bone 
biopsy is 
available) 
Decalcified bone 
histology and 
histochemistry 
Bone cells (osteoblasts, 
osteoclasts, bone lining cells, 
osteocytes, bone marrow, 
chondrocytes 
Routine bone and joint stains (H&E, 
Toluidne blue, Safarin O) or immune-
staining (TRAP, Factor VIII, PCNA, 
PGP9.5) 
High (if bone 
biopsy is 
available) 
Microscopy 
Bone structure, lamellar 
bone, woven bone, cellular  
analyses 
Polarized microscope, electron 
microscope 
High  
P1NP - serum type 1 procollagen (C-terminal/N-terminal); BSAP - serum bone-specific alkaline phosphatase; 
CTX - collagen type 1 cross-linked C-telopeptide; TRAP5b - tartrate-resistant acid phosphatase 5b; PIIANP - type I 
procollagen N-terminal propeptide; ICTP - carboxyterminal telopeptide of type I collagen; IGF-1 - insulin-like 
growth factor-1; PTH - parathyroid hormone; T3/T4 - thyroxine/triiodothyronine; PCNA - proliferating cell 
nuclear antigen; PGP9.5 - neuron cytoplasmic protein gene product also known as ubiquitin C-terminal 
hydrolase 1 (UCHL-1). 
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Radiological methods based on detecting bone minerals should always be used in 
combination with histology. Quantitative computed tomography (qCT), peripheral 
quantitative CT (pQCT) and micro CT (μCT) are additional techniques that are superior to X-
ray in assessing bone geometry, mass and structure. X-ray with/without pQCT is the method 
of choice for in vivo follow-up due to its good correlation with the mechanical testing of 
bone strength [104]. The strength of bone and callus assessed via the 3- and/or 4-point 
bending method (or torsional testing performed ex vivo) supplements the assessment of 
bone regeneration quality and provides opportunities to correlate and accurately interpret 
radiologic and other data (serum biomarkers, histology). Bone histology and histochemistry 
performed ex vivo provide key and quantifiable methods to test bone cell activity during 
bone regeneration and should be an integral part of bone healing animal studies. 
Undecalcified bone histomorphometry based on the use of fluorescent dyes such as calcein, 
tetracycline and alizarin labelling mineralizing bone surfaces provides an accurate 
quantification of the bone formation and resorption processes in the callus and in the 
surrounding cortical and cancellous bone. Differential staining using the van Kossa method 
for minerals and counterstaining with toluidine blue enables the meticulous evaluation of 
cartilage and mineralized bone at the callus. The same metacrylate embedded bone samples 
can also be used for polarized light microscopy for determining the lamellar or woven bone 
structure in the newly formed bone. Examples of the healing process in long bones by using 
radiology methods and histology is depicted in Figure 1B. Both methodologies can be used 
separately or in combination to accurately score the healing cascade in order to assess 
efficacy and safety of tested therapies.   
Serum and urine biomarkers of bone formation and resorption are highly desirable 
and recommended for the assessment of bone metabolism. Although serum biomarkers can 
be used to measure the overall activity of bone cells throughout the skeleton, and may not 
always detect local changes in bone activity around the fracture, these markers have a great 
translational value and as such provide an exceptional tool for accurately monitoring skeletal 
metabolism in live animals. 
4. 3R: Replacing, reducing and refining to improve animal welfare 
Although scientists are continually developing more complex alternative techniques, 
like engineered organs and in vitro tissue models, animal models are still the gold standard 
for fracture healing testing due to their ability to mimic complex human physiological 
processes and bone mechanics which cannot be simulated and replaced by even most 
advanced non-animal technologies. This is particularly true for testing of new medicinal 
products and during preclinical phases of drug development. Contemporary biomedical 
research projects are increasingly encountering efforts to apply the principles of the ”3Rs” 
for conducting humane experimentation in animals focused on Replacement, Reduction and 
Refinement [80,81]. 
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To align more firmly with the principles of the 3R, EU member states adopted the 
2010/63/EU directive and the same processes are being implemented by other policy 
makers: EMA (http://www.ema.europa.eu/ema/), the OECD (http://www.oecd.org/health/) 
and the ICH (http://www.ich.org/products/guidelines.html/).  
4.1. Animal model considerations 
Animal models of bone regeneration fall into two categories: (1) ectopic models are 
primarily used to distinguish between the proliferative and inductive capacity of new 
products, while (2) orthotopic models are used to test the efficacy and safety of the new 
products and/or procedures. Ectopic models are relatively simple, less costly and less 
invasive. For example, ectopic bone formation models were recently used to elucidate 
whether the maturation status of implanted cells determines the origin of tissue-engineered 
bone [105] and to demonstrate new bone formation after the implantation of the 
OSTEOGROW device (rhBMP6 in autologous blood coagulum) without any signs of 
inflammation or fibrosis [17]. Although successfully used as a preliminary model for 
screening various formulations of osteogenic cells, scaffolds and growth factors, the ectopic 
model displays serious limitations including the eventual reabsorption of newly formed bone 
and the lack of effective mechanical stimulus required for bone remodelling [106]. 
Orthotopic models represent investigational procedures performed in or around the bone 
itself. The classification of the bone healing models is presented in Figure 2. The process of 
bone repair can also be studied in models of bone disuse under various loading conditions 
via animal models in which one limb is fully or only partially deprived of weight bearing 
activity. These models are more sophisticated because they require multiple procedures 
such as sciadic neurectomy, amputation or various immobilization techniques combined 
with bone defects [107,108]. The choice of the model should be based on scientific, ethical 
and practical merits of a particular study and reflect the human biology or disease and 
should accommodate for appropriate clinical settings with relevance to the product being 
tested [101,109-111]. 
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Figure 2. Graphical presentation of animal bone models based on the investigated effect of 
the therapy. Ectopic models based on injection site are referenced as subcutaneous (s.c.), 
intramuscular (i.m.) and under the kidney capsule implantation (u.k.c.) models [16,112]. 
Based on the creation of the defect size, orthotopic models of bone healing are divided in a 
non-critical size defect models with the capacity to heal without an intervention, whereas in 
the critical size defect model, bone regeneration and restoration of the function will not 
occur without an intervention. Orthotopic models can also be grouped based on the 
anatomical location in the body (appendicular and axial skeleton) but also based on the bone 
structure and microanatomy of the bone being studied (cortical and/or cancellous bone). 
When based on mechanical loads imposed on the studied bone, animal models can resemble 
physiological and non-physiological conditions. For example, bone repair can be studied in 
non-loaded bones (such as calvarias), in bones that experience normal weight bearing loads 
(appendicular (vertebrae) or axial (long bones) skeleton) or in the mandible where non-
weight bearing intermittent loads occur during chewing [113,114]. Bone defect studies can 
be performed in traditional laboratory animals (mice, rats, rabbits, dogs and non-human 
primates - NHP) as well as in domestic animals such as sheep and pigs, which are often used 
as viable substitutes for dogs and NHP. 
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Systematic factors discussed in the section 3.1 of this manuscript should be taken 
into account during the planning phase of the study. Models that are better understood and 
described in the literature often have proven records of being more predictive of clinical 
outcomes. The age of study animals as well as gender can influence the bone repair through 
the action of calciotropic hormones and thus merit careful consideration [115-119].  For 
example, aged, thyroparathyroidectomized and ovariectomized (OVX) animals are known for 
delayed fracture healing and reduced bone mineral density; therefore, OVX animals are 
frequently utilized to study osteoporotic fractures because these models mimic 
postmenopausal women [88,120,121]. Historic evidence suggests that rats, rabbits and mice 
are the most frequently used species to study bone physiology and drug efficacy and safety 
accounting for approximately 80% of all animals used to study bone repair, while other 
species including sheep, goats, pigs, dogs and non-human primates (NHP) make up for the 
remaining 20% [122,123]. The choice of a particular species is a critical step and is often 
based on the biochemical and microstructural characteristics of the bone tissue as well as on 
the similarities of the healing processes between the particular species and humans (Table 2, 
Figure 1). In addition, difference in gross anatomy as well as differences in distribution of the 
cortical and cancellous bone compartment within each bone should be taken into account 
when deciding which species to choose for the particular study since those differences 
reflect biomechanical properties that play a critical role in the bone repair processes [124]. 
The availability of serum biomarkers and the translatability of biomarkers to the clinical 
environment is a very important issue. Rats, dogs and NHP are routinely used in preclinical 
safety studies and serum biomarkers of bone metabolism are well established and validated, 
therefore using those species is advantageous from a biomarker standpoint; however, the 
use of dogs and NHP is restricted and those two species should only be used if necessary 
only for the late stage testing of efficacy and safety parameters. Clearly, no animal model 
entirely mimics human conditions because no animal species has a skeletal or biomechanical 
properties identical to human. Additional factors that could influence selection of the animal 
model include the size of the animal, the cost to acquire and care for animals, animal 
availability, ethical acceptability, tolerance to captivity, breeding cycles, ease of housing and 
handling, adequate facilities and qualified staff and familiarity with the model, technical 
capacities etc. [109,110,125]. 
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Table 2. Bone research related characteristics of laboratory animals. 
Laboratory animal 
Life expectancy 
(months) 
Bone maturation
2
 
(epiphyseal plate 
closure) (months)  
Time to 
union of 
fractures 
(weeks) 
Similarity to 
human bone 
(Ma+Mi+C+R)
5
  
Ethical 
acceptance 
Mouse 18-36 5 3 0+1+0+1 = 2 high 
Rat (Sprague-Dawley) 30-48 11 4-6 1+1+0+1 = 3 high 
Rabbit (New Zealand 
White) 
84-96 
6,8 tibia 
6-7 1+1+2+1 = 5 high 
5,3 femur 
Dog (Grayhound) 108-168 
7,5 tibia 
10-13 2+2+3+2 = 9 low 
7,3 femur 
Sheep (Suffolk x 
Dorset) 
180 17 10-14 3+1+2+2 = 8 medium 
Pig (Gottingen) 180+ 
12-24
3
 
12-24 2+2+3+3 = 10 medium 
28 femur
4
 
Monkey (Rhesus) 240-360 75 femur
5
 16-24 3+3+3+3 = 12 low 
Human 47-83 years
1
 240 18-24 - - 
1
 WHO Life expectancy at birth, both sexes, 2011; 
2
 ref [126]; 
3
 ref [127]; 
4
 ref [128]; 
5
 ref [129]; 
5
 adapted from 
[110] – comparison based on macrostructure (Ma), microstructure (Mi), composition (C) and remodelling (R) 
and scoring from 0 (not similar)-3 (very similar) resulting in the total sum representing similarity. 
 
4.2. Species Skeleton Specification 
 
4.2.1. Rodents 
Of all laboratory animals mice and rats are considered to have skeletons and bone 
biologies that are least similar to humans since their skeletons are modelling-driven due to 
permanently open growth plates at the epiphyses of long bones, a lack of the Haversian 
system and low cancellous bone content at the epiphyses of the long bones [100,130-136]. 
However, studies in rodents are very informative and cost effective. Rodents, primarily mice 
are genetically very well defined and are best suited for studies with genetically modified 
strains to address specific molecular mechanisms of bone physiology and pathology. The 
advantages of using rodents, and particularly rats in early stage studies are numerous and 
include broad availability, inexpensive housing, easy handling, small size (relatively small 
quantities of test article needed), well-defined and described procedures and models and 
biomarker availability. Rats are most regularly used in safety toxicology studies and also to 
study the pharmacodynamic and pharmacokinetic properties of novel treatments [137]. 
Despite some deficiencies, rat models of skeletal diseases are very predictive of drug efficacy 
and safety in humans because bone cells, osteoblasts, osteocytes and osteoclasts in rats 
have similar receptors to human bone cells and therefore react to drug challenge in a similar 
fashion to human bone [85]. Some characteristics of rodent models, such as an open growth 
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plate, may be unfavourable for studies focusing on the adult skeleton, however, studies in 
rodents are very useful when investigating efficacy and safety of drugs targeting juveniles. 
ICH-harmonized guidelines for biotechnology-derived pharmaceuticals were recently 
updated to stress the importance of selecting the relevant species for the investigational 
product biological activity as well as for the safety [138]. 
4.2.2. Rabbit 
Rabbits are the smallest commonly used non-rodent species in musculoskeletal 
research studies [139] because the rabbit skeleton does not include the two major 
drawbacks of rodent models; the lack of the Haversian system and permanently open 
growth plates. Rabbit bone also differs from that of humans in its size and shape [124]. 
Histologically, the skeleton of rabbits consists of primary lamellar bone while vascular canals 
parallel the long bone axis. Rabbits are commonly used models for bone healing studies due 
to the vast experience with rabbit handling, short duration necessary to reach the mature 
bone characteristics and bone densities that are similar to those of humans [103,140]. 
Rabbit models were used to study metaphyseal fractures [141], mandibular distraction 
osteogenesis [142], mandibular defect repair [143], investigational products in cranial 
models [144], critical size defects in animals of different age [145] and spinal fusion 
[146,147]. Rabbits are also widely used to study novel biomaterials, growth factors and 
stem-cells approaches [142-145,148,149]. 
4.2.3. Dog 
Canine bone healing models are frequently used in musculoskeletal and dental 
research because significant amounts of information are available regarding the 
predictability of these models for human conditions [110,140,150].  Dog bones have a mixed 
microstructure with a primarily secondary osteonal bone and a plexiform bone in the vicinity 
of the periosteum and endosteum [140]. The bone composition in dogs is similar to that of 
humans and the structural properties of bones from several skeletal sites was recently 
summarized by Bagi et al. [124]. Dogs are often used in safety studies as a second species 
and biomarkers of bone metabolism are validated and are well-established for dogs. 
However, there are societal concerns regarding the use of dogs in biomedical research and 
the ethical framework related to their welfare [151] consistently restricts the use of dogs in 
preclinical testing. 
4.2.4. Pig 
Although pigs have been used for decades in bone studies this model was never 
widely deployed due to the fact that commercial breeds usually grow quickly and reach 
extreme body weights. With advances in the breeding of minipigs and micropigs, the use of 
pigs in biomedical and orthopaedic research has increased [152]. Regarding bone anatomy, 
microstructure, remodelling and healing, porcine bone closely resembles human bone 
[153,154]. Pigs were found to exhibit spontaneous vertebral fracture and their rates of bone 
15 
 
removal and deposition (trabecular and cortical bones) are similar to humans although 
porcine bone remodels slightly faster than human bone [152,155,156]. Limitations for the 
use of NHP in regulatory toxicology studies have opened discussions on the suitability of 
using minipigs in drug development studies [157]. Recently, it was shown that minipigs are 
comparable to NHP in immunogenicity testing [158,159] and their liver metabolism is similar 
to that of humans [160]. Additionally, models of porcine osteoporosis have been developed 
to expand the usefulness of this species for bone research [161-164]. 
4.2.5. Sheep 
Sheep tibia models are considered to be valid and reliable for the evaluation of bone 
regeneration, with the advantage of having a maximal weight bearing scenario and long 
bone dimensions in adult animals that are suitable for the testing of human implants and 
prostheses [165-168]. However, sheep are seasonal breeders so their bone metabolism 
changes during the year which presents a significant hurdle for bone metabolism studies. 
The bone maturation period in sheep is long and the microstructure in the young animals is 
distinct (plexiform bone). In adult sheep, the bone structure is different from humans, 
consists primarily of primary bone and Haversian remodelling occurs during adulthood [110]. 
The bone mineral density and bone strength in sheep is increased relative to human. 
Moreover, sheep models of critical size defects are extensively applied to evaluate cell-based 
therapeutic approaches using autologues, allogeneic or xenogeneic MPCs in combination 
with growth factors and different types of scaffolds to enhance bone regeneration showing 
significant advantages compared with cell-unloaded (empty) scaffolds [43,53,166,169-176]. 
4.2.6. Non-Human Primates 
NHP are the best characterized large animal model for skeletal research and their 
skeleton and posture as well as their bone structure, composition and remodelling patterns 
is similar to those of humans [124,177-179]. In addition to a high similarity between 
monkeys and humans regarding drug metabolism between monkey and human, the 
existence of validated serum and urine biomarkers with high translational value to human is 
of the outmost importance for regulatory studies using NHP. Although skeletal studies in Old 
World primates yield valuable data, the use of NHP are constrained by ethical and technical 
considerations, including high cost, limited availability and regulations (Directive 
2010/63/EU) [80,180]. Although very useful in bone research for novel therapies, NHPs 
should only be used in situations when efficacy, safety and toxicity studies in other species 
could not provide appropriate answers i.e. human antibodies or indications such as 
hereditary non-union of the tibia or long bone fibrodisplasia. Marmosets were recently 
proposed as good alternative for skeleton studies because the adult marmoset skeleton has 
similar anatomical characteristics that are similar to those of adult humans, including the 
absence of growth plates, the presence of Haversian system and true remodeling of 
cancellous and cortical bone [181,182]. Compared with macaques, marmoset monkeys have 
an earlier puberty and sexual maturity and presumably achieve earlier peak bone mass. They 
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are easy to breed and to handle under controlled laboratory housing conditions. Similar to 
FDA guidelines [183], in the EMA Guideline on the evaluation of new medical products in the 
treatment of primary osteoporosis [184] states, that these substances should be tested in at 
least two species, one of which should be an ovariectomized rat and the other an animal 
with evaluable cortical bone remodeling. Primates, sheep and pigs are suggested as a second 
animal model by the EMA. Common marmoset monkeys (Callithrix jacchus) also fulfill these 
requirements because they show osteonal remodeling that is very similar to that of humans. 
It is therefore highly recommended that institutions involved in drug development request a 
scientific advice from regulatory agencies for opinions regarding non-clinical data 
requirements prior to firsts-in-human studies [184]. 
4.3. Animal models in cell-based therapies 
To be able to utilize the major advantages of experimentation in laboratory animals, 
models of bone repair need to be optimized in accordance to the unique characteristics and 
requirements of different species. Different cell-based therapy approaches to treat 
segmental defects in weight-bearing long bones are given in Table 3 to illustrate the great 
variability of models regarding cell population and scaffold selection, protocols of intra-
defect transplantation, species and defect localization, follow-up period and outcome 
measurements. Considering the wide diversity of conducted research, investigators should 
be extremely cautious to translate conclusion in-between models and species and pay 
special attention in designing the animal studies to draw valuable and reproducible results. 
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Table 3. Different cell-based therapeutic approaches used for the treatment of critical size 
segmental long bone defect in small and large animal models  
 
Cell-based therapy 
Species (study reference and details) 
Rodent Non-rodent 
autologous (syngeneic) 
or allogeneic BM-
derived MPCs 
Mouse: [185], [186] 
Rat: [187] (DM), [188]  
Rabbit: [189], [190], [191], [192]  
Dog: [193], [194] 
Sheep/Goat: [167], [170], [176], [195], 
[196], [197] 
human BM-derived 
MPCs 
Mouse: [198] 
Rat: [199], [200], [201] 
Rabbit: [202] 
Sheep: [203] 
non BM-derived MPCs 
or non-MPC cell-based 
therapy
2
 
Mouse: [204] (hUCPVC), [205] 
(hSDF1/hBMP2-mFTG) 
Rat: [206] (rEPC), [207] (hADPVC) 
Rabbit: [208] (rbPMPC), [209] (rbADPVC), 
[210] (rbDFAT) 
Sheep: [6] (sEPC) 
genetically modified or 
labeled MPCs
1
 
Mouse: [211], [212] (hBMP2-mMPC), 
[213] ( hMPC/GFPCol1α1), [214] 
(mMPC/GFP), [215] (ShhN-mPDMPC) 
Rat: [216] (BMP7-rDF), [217] (hBMP2-
rMPC), [45] (hBMP2-MDC or hBMP2-ADC) 
Rabbit: [218] (bFGF-rbMPC), [149] 
(rbMPC/ferumoxide),[219] (hAng1-
rbMPCs/PRP), [220] (hVEGF-rbMPC/PRP) 
Minipig: [221] (hBMP2/hVEGF-pADMPC), 
[222] (US2/US3-pADMPC) 
MPCs with growth 
factors/compounds 
Mouse:  [223] (hVEGF/hMPC), [224] 
(hVEGF/hBMP2/hMPC) 
Rat: [225] (hBMP2/hMPC), [226] 
(hBMP7/hMPC) 
Rabbit: [227], [228] (PRP/rbMPC),  
Dog: [229] (PRP/cMPC) 
Sheep: [43], [174] (sMPC/PRP), [230] 
(hBMP7/sMPC) 
 1
 Cells were genetically modified by viral or non-viral transfection to overexpress different growth factors or regulatory 
molecules. Cells transfected with US2/US3 genes downregulated MHC I expression. In some studies MPCs were 
fluorescently labeled for in vivo tracking.  
2
Non bone marrow-derived MPCs were isolated form adipose tissue, periosteum, muscle, articular cartilage, placenta, 
human umbilical cord blood, etc. Therapy with cells other than MPCs used endothelial progenitor cells or genetically 
modified fat cells. 
Abbreviations: BM - bone marrow; h - human; m - mouse; r - rat; rb - rabbit, s - sheep; MPCs - mesenchymal progenitor 
cells; GFP - green fluorescent protein; DM - diabetes mellitus prone strain; BMP - bone morphogenetic protein; VEGF - 
vascular endothelial growth factor; PRP - platelet-rich plasma; Shhn - N-terminal sonic hedgehog peptide; UCPVC - umbilical 
cord perivascular cells; EPC - endothelial progenitor cells; bFGF - basic fibroblast growth factor; Ang1 - angiopoietin 1; MHC 
- major histocompatibility complex; SDF1 - stromal cell derived factor 1; FT - fat tissue graft; DFAT - adipocyte-derived 
dedifferentiated fat; Col1α1 - Collagen, type I, alpha 1; PDMPC - periosteal-derived mesenchymal progenitor cells; MDC - 
muscle-derived cells; ADC - adipose tissue-derived cells; DF - dermal fibroblasts; ADPVC - adipose tissue-derived 
perivascular cells, PMPC - placenta-derived mesenchymal progenitor cells  
 
5. Experimental design and statistical considerations for animal fracture models 
Here we describe a few possible modes for the standardization of the non-clinical 
efficacy evaluation of new treatments using the examples of critical and non-critical size 
defects of long bones in rat and rabbit models. We suggest that in both paradigms µCT (in 
vivo or ex-vivo; bone volume/tissue volume ratio), X-ray (rabbit in vivo) and histology are 
used; the latter two employing the elaborated scoring system shown in Figure 1. These 
methods and measures are reliable and reproducible with comparable mild-to-moderate 
variability in treated and control animals with relative standard deviation (RSD) in the range 
of 10-30% [231,232]. 
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5.1. Critical size defect 
 Because the defect does not heal spontaneously and remains practically unchanged 
in control animals, evaluation at any time-point after the initial 1-2 weeks could indicate a 
bone-healing effect. However, we suggest that the evaluation of new treatments should be 
compared with the approved treatments, with main assessments based on repeated in vivo 
radiological measures over a period extending beyond the expected time of physiological 
union seconded in non-critical size fractures focusing on the overall process (Figure 1). 
Experiments should include only a few previously demonstrated inactive control animals 
(“placebo” to the new treatment). Figure 3A depicts four repeated radiograms and μCT 
scans (table in Figure 3A) taken over time in one such experiment. Data demonstrate low 
variability of values across the time point. We suggest data analysis by fitting general linear 
mixed models (GLMMs) with restricted maximum likelihood (REML) estimation (relaxed 
assumptions as compared to repeated measures ANOVA, units with individual missing values 
not excluded) to produce time-averaged difference between treatments. An alternative 
analysis would be based on integration of the response as the area under the curve (AUC) of 
change of the radiological measure (a difference between newly formed bone at each time 
point vs. 0) by fitting a general linear model (GLM). We suggest that the defect size is 
considered as a covariate. Figure 3A, B depicts a new treatment superior to an approved one 
(bone formation 4,6 fold greater based on time-averaged response and 2,9 fold greater 
based on AUC). We suggest that a new treatment indicates a potential superiority if any of 
these measures is at least 25% in its favour.  With four repeated assessments, assuming 
variability as depicted in Figure 3 (or relative standard deviation (RSD) around 20% at each 
time point, as well as for AUC) autocorrelation 0.6 and autoregressive (1) [AR(1)] covariance 
structure, 7 animals per group per time-point provide 80% power to detect such a difference 
at a two-sided α=0.05. The same sample size applies for 25% difference in AUC. Adding a 
treatment time interaction term in GLMM allows for comparisons at different time points, 
but requires adjustments of comparison-wise alpha level, resulting in a need for a larger 
sample (e.g. for pairwise comparison at four time points, under the above conditions 17-18 
animals per group). To detect a time-averaged or AUC difference of at least 15% under the 
above conditions, 17-20 animals per group are needed. If such an experiment fails to reject 
null-hypothesis, it is reasonable to conclude that the test is comparable to the reference. We 
suggest that if the entire 95% confidence interval around the difference falls within the 
range -15% to +15%, it is plausible to conclude equivalence of two treatments. With 17-20 
animals per group, the experiment provides >80% power to even formally demonstrate 
equivalence under the above conditions. 
5.2. Non-critical size defect 
The same approach with repeated assessment in vivo can be applied to the non-critical size 
defect model. We suggest that animals should be scanned immediately after the fracture – if 
non-zero values are present and an adjustment for baseline should be considered. Since the 
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defect heals spontaneously, assessment very early or late in the process are biased towards 
“no difference”. It could also be difficult to distinguish between different active treatments. 
We suggest that a test treatment (T) should be considered effective if it yields by at least 
30% higher healing “scores” around mid-time of the spontaneous process as compared to an 
inactive control (Ctr). Figure 3C depicts an experiment in which several active and 
“disruptive” treatments were assessed along with the inactive control at the single time-
point late in the healing process (ex vivo rat bone, μCT). Data analysis (GLM) requires 
adjustment for pairwise comparisons. Figure 3D depicts a hypothetical experiment in which 
a treatment is evaluated against an inactive control ex vivo at two time points around the 
mid-time of the process. If comprises one between-group factor with four levels (2 
treatments x 2 time points) and should be analysed in a GLM with adjustments for two post-
hoc comparisons of interest (T-1 vs. Ctr-1; T-2 vs. Ctr-2). With group RSD of 20%, 10 animals 
per group are needed (40 total) to detect a 30 % difference between T and Ctr at any of the 
two assessments. 
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Figure 3. A. X-ray of critical size defects of rabbit ulnae treated with a BMP6 in the modified 
whole blood coagulum (WBCD) and commercial BMP7 device and assessed at 0, 2, 4, 6 and 8 
weeks after surgery. Tabulated data show corresponding BV/TV ratios obtained by μCT 
[233]. B. Graphical representation of BV/TV% over time (mean±SD; n=8). A GLMM fitted to 
ln-transformed data to determine time-averaged difference (weeks 2-8) indicated around 
4,6 times greater response with BMP6. A GLMM fitted to In-transformed data to determine 
the time-averaged difference (weeks 2-8) indicate around 4,6 times greater response with 
BMP6. A GLM fitted to ln-transformed AUC of BV/TV% difference at weeks 2-8 vs. time 0 
indicated around 2,9 times greater response (tabulated GMR). The insert shows a quadratic 
fit with 95%CI of prediction indicating that the effects of two treatments were not likely to 
“meet” even after 10+ weeks post-surgery. The intrapolated grey line indicates a 
hypothetical treatment not relevantly different vs. the approved one (<15% difference). C. 
μCT imaging of rat femurs ex vivo at 6 weeks after osteotomy in the proximal third of the 
femur. The rats were randomly assigned to one of the following groups: control; BMP1-3 
antibody i.v. (50 ug, 1xwk); BMP1-3 i.v. (3 ug, 3x7wk); BMP6 i.v. (250 ug/kg, 2x/wk) and 
BMP1-3 (3 ug, 3x/wk) +BMP6 i.v. (250 μg, 2x/wk) therapy (mean±SD, n=6) [234]. D. Outline 
of a hypothetical experiment in which tested treatment (T) and a control (Ctr) are assessed 
ex-vivo at two time points (1, 2) around midtime of the spontaneous healing process. Data 
are independent, i.e., there are four groups of animals (2 treatments x 2 time points). GLMM 
- general linear mixed models; GMR - geometric mean ratios; AUC - area under the curve; BV 
- bone volume; TV - tissue volume; GLM - general linear model.  
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6. Suggested guidelines for animal use in bone repair experimentation 
To enable the collection of reliable data regarding the efficacy and safety of tested 
substances, animal models and methods should be carefully selected and combined to guide 
clinical studies so that the much-needed treatments aimed to facilitate the tissue 
regeneration process will ultimately reach the patient. Below are suggested guiding 
principles for conducting animal studies in bone repair scenarios. 
1. The skeletal characteristics of each species must be considered when judging the 
translation of preclinical data to the human clinical situation. The rat model, despite its’ 
limitations, remains the most informative small animal model and should be the first 
choice to initiate in vivo assessment. If studies in large animals are planned, the best 
option is to combine efficacy and safety study in the same species. Although NHPs are 
the best choice due to the high similarity to human outcomes, dogs or pigs are valid 
alternatives. To bridge the gap between rats and large animals, the use of 
“intermediary” models (marmoset or rabbit) could be considered with a caveat that 
these models may not provide sufficient new information to better guide studies in 
large animals.  
2. The dosing and sample size must be based on previous in vitro studies as well as the 
healing biology of a specified indication and healing time point analyses, respectively. 3R 
principles should always be used in designing experimental protocols. 
3. Efficacy testing in animal models should mimic the intended clinical indication.   
4. Appropriate methods and markers must be chosen for the assessment of bone healing 
process as suggested in Table 1. Radiologic techniques in combination with histology, 
bone mechanics and serum and urine biomarkers are recommended.  
5. The scanning of animals prior to recruitment will enable each animal to serve as its own 
control and ensure screening for potential fractures or malformations, establishing 
growth plate status and skeletal maturity to avoid biological variation errors.  
6. A bone healing assessment plan should be carefully designed while bearing in mind the 
callus formation time course and the points of biomechanical bone restoration in 
different animal species. Primary and secondary end points of the study and scoring 
system should be carefully considered and specified in advance. 
7. The chosen model, surgical and therapeutical procedures, variability, sample size and 
percent of expected outcomes should be supported by detailed and justified pre-
experimental statistical analysis. 
8. The safety and tolerability of the therapy should be monitored during the study and 
synchronized with regulatory documents whenever possible.  
9. Isolated MPCs should be characterized by phenotype, gene expression profile and 
functional testing prior the grafting procedure. Markers for labelling the target 
osteoprogenitor population and lineage tracing approach are particularly useful for the 
in vivo tracking of the transplant. Cell-based engineered constructs could be harvested 
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at different time-points post-surgery and analyzed ex vivo to evaluate the viability, 
proliferation and differentiation of the transplanted cells. 
10. Cell based therapies in combination with biomolecules and biomaterials require 
additional evaluation particularly regarding osteogenic differentiation of transplanted 
cells and graft-host integration. Moreover, construct vascularization, scaffold 
biodegradation and transplant-host integration are important predictors of skeletal 
tissue regeneration. Local and systemic immune reactions should also be monitored 
particularly in the case of allogeneic or xenogeneic grafts. 
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